48 results on '"Lakatos, P.L."'
Search Results
2. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort
3. PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE
4. P727 Change in Crohn's disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
5. P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey
6. P411 Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
7. P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database
8. P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
9. P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort
10. P309 Impact of rapid access MR on clinical decision making and patient management in Crohn's disease in a tertiary referral center
11. P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data
12. P152 Reconsidering the prognostic value of traditional serologic antibodies in Crohn's disease – immunoglobulin classes to take the centre stage
13. P145 Measuring access and quality of care indicators in inflammatory bowel disease in a tertiary referral center
14. AB0314 Awareness and Acceptance of Biosimilars by Rheumatologists in Eleven Eu Countries
15. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
16. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort
17. Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study
18. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe — An ECCO-EpiCom study
19. P557 Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy
20. P321 The one-year efficacy of infliximab does not depend on the timing of biological therapy in ulcerative colitis
21. DOP074 Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis
22. DOP028 Development of red flags for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative
23. P649 Relationship between clinical characteristics and vitamin D receptor polymorphisms in Crohn's disease
24. P344 Short and medium term efficacy of adalimumab in ulcerative colitis – a multicentre, prospective observational study
25. P321 Vitamin D level doesn't correlate with disease extent and severity in Hungarian patients with inflammatory bowel disease
26. P402 Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy
27. P460 Is it necessary to perform x-ray absorptiometry in young IBD patients to predict the risk of fracture?
28. 183 MANNOSE-BINDING LECTIN DEFICIENCY CONFERS RISK FOR INFECTIONS IN A LARGE HUNGARIAN COHORT OF PATIENTS WITH LIVER CIRRHOSIS
29. P133 - Adherence to therapy and use of complementary and alternative medicine in patients with inflammatory bowel diseases
30. P226 - High incidence of Crohn's disease in Western Hungary between 2002 2006
31. P129 - The impact of concomitant treatment with immuno-modulators and antibiotics on the outcome of C. difficile-associated inflammatory bowel disease exacerbation: an ECCO multi-center retrospective study
32. 8 - Azathioprine/biological therapy does prevent surgery but not reoperation in smokers with Crohn's disease
33. P295 - MBL level and deficiency is not associated with either Crohn's disease or ulcerative colitis, disease phenotype, CRP, serology profile and NOD2/CARD15 genotype in a large Hungarian IBD cohort, but was associated to the lack of TLR4 variants in CD
34. P015 - Pancreatic autoantibodies are associated with reactivity to microbial antibodies penetrating disease behavior perianal disease and extraintestinal manifestations but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort
35. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients
36. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
37. P285 COMPARING CONVENTIONAL AND GASCA TESTS FOR THE DIAGNOSIS AND DETERMINATION OF CLINICAL PHENOTYPE IN CROHN'S DISEASE
38. P209 NFKBIA 3'UTR AND NFKB1 -94INS/DELATTG VARIANTS IN HUNGARIAN IBD PATIENTS: THE 3'UTR VARIANT IS ASSOCIATED WITH EXTENSIVE COLITIS
39. P208 IL-23 RECEPTOR (IL-23R) GENE PROTECTS AGAINST CROHN'S DISEASE IN HUNGARIAN PATIENTS
40. P058 EVALUATION OF THE COMBINED APPLICATION OF ETHANOL-FIXED AND FORMALDEHYDE-FIXED NEUTROPHIL SUBSTRATES FOR IDENTIFYING ATYPICAL P-ANCA IN INFLAMMATORY BOWEL DISEASE: SPECIFICITY AND REPRODUCIBILITY
41. P237 INTERACTION BETWEEN SEROREACTIVITY TO MICROBIAL ANTIGENS AND GENETICS IN CROHN'S DISEASE: IS THERE A ROLE FOR DEFENSINS?
42. P253 NEW SEROLOGICAL MARKERS FOR INFLAMMATORY BOWEL DISEASE ARE ASSOCIATED WITH EARLIER AGE AT ONSET, COMPLICATED DISEASE BEHAVIOR, RISK FOR SURGERY, AND NOD2/CARD15 GENOTYPE IN A HUNGARIAN IBD COHORT
43. P236 ASSOCIATION OF β-DEFENSIN 1 SINGLE NUCLEOTIDE POLYMORPHISMS WITH CROHN'S DISEASE
44. NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease
45. P120 THE ATP-BINDING CASSETTE TRANSPORTER ABCG2 (BCRP) AND ABCB1 (MDR1) VARIANTS ARE NOT ASSOCIATED WITH DISEASE SUSCEPTIBILITY, DISEASE PHENOTYPE, RESPONSE TO MEDICAL THERAPY OR NEED FOR SURGERY IN HUNGARIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
46. 250 Increased nociceptin and nocistatin in plasma, cerebrospinal fluid and tumor tissue indicates altered opioid system in rats with experimental hepatocellular carcinoma
47. Collagen type 1A1 gene SP1 polymorphism and bone disease in primary biliary cirrhosis
48. Autonomic and sensory nerve dysfunction in patients with Wilson disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.